Company profile

Garo H. Armen
Fiscal year end
Former names
IRS number

AGEN stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


9 Nov 20
24 Nov 20
31 Dec 20


Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Agenus earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
20 Nov 20 Armen Garo H Common Stock Grant Aquire A No 3.65 4,049 14.78K 412,645
6 Nov 20 Armen Garo H Common Stock Grant Aquire A No 3.82 3,869 14.78K 343,496
23 Oct 20 Armen Garo H Common Stock Grant Aquire A No 3.94 3,751 14.78K 339,627
9 Oct 20 Armen Garo H Common Stock Grant Aquire A No 4.35 3,397 14.78K 335,876
53.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 137 138 -0.7%
Opened positions 22 33 -33.3%
Closed positions 23 14 +64.3%
Increased positions 52 47 +10.6%
Reduced positions 34 25 +36.0%
13F shares
Current Prev Q Change
Total value 563.01M 410.21M +37.2%
Total shares 101.63M 89.86M +13.1%
Total puts 336.6K 111.9K +200.8%
Total calls 777.2K 913.91K -15.0%
Total put/call ratio 0.4 0.1 +253.7%
Largest owners
Shares Value Change
BLK BlackRock 13.48M $53.93M +8.4%
Oracle Investment Management 13.13M $52.54M +95.4%
RTW Investments 12.86M $51.46M 0.0%
Vanguard 8.55M $34.19M +9.7%
Cormorant Asset Management 8.5M $34M -22.7%
Artal 6.9M $27.6M +142.1%
STT State Street 6.73M $26.9M +1.6%
Boxer Capital 4M $16M 0.0%
Millennium Management 2.39M $9.58M +2.3%
Geode Capital Management 2.24M $8.98M +9.7%
Largest transactions
Shares Bought/sold Change
Oracle Investment Management 13.13M +6.41M +95.4%
Artal 6.9M +4.05M +142.1%
Cormorant Asset Management 8.5M -2.5M -22.7%
BLK BlackRock 13.48M +1.04M +8.4%
Ikarian Capital 950K +950K NEW
Acuta Capital Partners 0 -932.5K EXIT
Assenagon Asset Management 809.25K +809.25K NEW
Vanguard 8.55M +752.65K +9.7%
N Price T Rowe Associates 1.2M -670.2K -35.9%
Citadel Advisors 276.8K -630.43K -69.5%

Financial report summary

  • Risks Related to Our Financial Position and Need for Additional Capital
  • We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.
  • We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we will not be able to complete the development and commercialization of our product candidates.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • The nature and length of our operating history may make it difficult to evaluate our technology and product development capabilities and predict our future performance.
  • Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
  • Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements, and it is possible that such report on our financial statements may include such an explanation again in the future.
  • Risks Related to the Development of Our Product Candidates
  • Our business is highly dependent on the success of our balstilimab and zalifrelimab programs targeting second-line cervical cancer, which still require significant additional clinical development.
  • The successful development of immune modulating antibodies, including our balstilimab and zalifrelimab programs, is highly uncertain.
  • Our clinical trials or those of our future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.
  • Positive results from preclinical and clinical studies of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier studies of our product candidates in our later studies and future clinical trials, we may be unable to successfully develop, obtain regulatory for and commercialize our product candidates.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The number of product candidates that we are attempting to simultaneously advance creates a significant strain on our resources and may prevent us from successfully advancing any product candidates. If due to our limited resources and access to capital, we may prioritize development of certain product candidates, such decisions may prove to be wrong and may adversely affect our business.
  • Risks Related to the Commercialization of Our Product Candidates
  • If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.
  • We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • Even if our product candidates receive marketing approval, such products may fail to achieve the degree of market acceptance by physicians, patients, third- party payors and others in the medical community necessary for commercial success.
  • Even if we are able to commercialize any product candidates, such products may not receive coverage or may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, all of which would harm our business.
  • The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small, and our estimates of the prevalence of our target patient populations may be inaccurate.
  • We are currently building a marketing and sales organization and have no experience in marketing, selling and distributing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.
  • Risks Related to Manufacturing and Supply
  • Risks Related to Our Reliance on Third Parties
  • We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.
  • Risks Related to Government Regulations
  • The regulatory approval process for our product candidates in the United States, European Union and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.
  • The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.
  • The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, which may be difficult to predict.
  • Breakthrough Therapy Designation, Fast Track Designation or Regenerative Medicine Advanced Therapy Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that any of our product candidates will receive marketing approval in the United States.
  • We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.
  • We may not be able to obtain or maintain orphan drug designations from the FDA for our current and future product candidates, as applicable.
  • Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti- kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
  • Even if we receive regulatory approval of any product candidates or therapies, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Healthcare insurance coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates or therapies profitably.
  • Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.
  • European Union drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.
  • European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.
  • Laws and regulations governing any international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.
  • Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • If we do not comply with environmental laws and regulations, we may incur significant costs and potential disruption to our business.
  • Risks associated with doing business internationally could negatively affect our business.
  • The exit of the UK from the European Union may materially affect the regulatory regime that governs our handling of EU personal data and expose us to legal and business risks under European data privacy and protection law.
  • Comprehensive tax reform legislation could adversely affect our business and financial condition.
  • Our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.
  • If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.
  • If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates.
  • We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.
  • If we do not obtain patent term extension and/or data exclusivity for any product candidates we may develop, our business may be materially harmed.
  • We may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats.
  • Risks Related to Business Operations, Employee Matters and Managing Growth
  • We have undergone significant growth across multiple locations over the past few years, and are focusing on further enhancing core areas and capabilities as we move toward commercialization. In addition, we have consolidated certain sites while expanding others to focus on our core priorities and future needs. We may encounter difficulties in managing these growth and/or consolidation efforts, either of which could disrupt our operations.
  • Product liability and other claims against us may reduce demand for our products and/or result in substantial damages.
  • Our internal computer systems, or those of our third-party CROs, CMOs, licensees, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption in our business and operations or could subject us to sanctions and penalties that could have a material adverse effect on our reputation or financial condition.
  • Natural or man-made calamities could disrupt our business and materially adversely affect our operations.
  • Failure to realize the anticipated benefits of our strategic acquisitions and licensing transactions could adversely affect our business, operations and financial condition.
  • We intend to advance our cell therapy business through our subsidiary, AgenTus Therapeutics, eventually with separate funding. Moving intellectual property assets into AgenTus Therapeutics in foreign jurisdictions could have adverse tax consequences, and there is no guarantee that we will be able to attract external funding. Moreover, even if the business is funded, there is no guarantee that it will be successful.
  • Risks Related to our Common Stock
  • Our stock has historically had low trading volume, and its public trading price has been volatile.
  • We are a “Smaller Reporting Company”, and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • We do not intend to pay cash dividends on our common stock and, consequently your ability to obtain a return on your investment will depend on appreciation in the price of our common stock.
  • The sale of a significant number of shares could cause the market price of our stock to decline.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • We have broad discretion in the use of our existing cash, cash equivalents and investments and may not use them effectively.
  • If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
Content analysis ?
H.S. junior Good
New words: arose, Baili, bearing, dental, equal, Evan, lump, outplacement, predicated, Secretary, sublicensable, TGF, unvested, USto, Vice, voluntarily
Removed: CMV, CSL, Leap, Potenza, progression, secured, Suzhou